Professional antigen-presenting cells—monocytes and macrophages—engulf these proteins, digest them into short peptide ...

Phase 1/2 study ongoing, initial clinical data expected in 3Q 2026 Cash balance of $23.9 million as of March 31, 2026 anticipated to fund operations into 2027, including completion of the dose ...

Conventional immune checkpoint inhibitors, such as anti-PD-1/PD-L1 and anti-CTLA-4 antibodies, can reinvigorate T cells but ...

MMRd showed no meaningful association with pOR, pCR, or RFS, suggesting limited utility for selecting patients for Gem-iDRS ...

Cancer immunotherapy has saved lives, but it often falls short due to off-target toxicity and weak tumor-specific immune ...